Last edition
News about "obesity treatment "
Harbour BioMed Reports Promising Preclinical Data for AI-Driven Drug Candidate LET003
Harbour BioMed announced promising preclinical data for LET003, its first Artificial Intelligence (AI)-enabled drug candidate, highlighting potential as a next-generation obesity therapy targeting ACVR2A/2B.
Obesity Treatment | 18/05/2026 | By News Bureau | 239
Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials
Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.
Obesity Treatment | 13/05/2026 | By News Bureau
Neuland Laboratories partnership with LIR Life Sciences Corp will focus on developing and manufacturing cell-penetrating peptides to support LIR Life’s patch-based GLP-1/GIP obesity treatment platform.
Obesity Treatment | 07/05/2026 | By News Bureau | 108
Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118
Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.
Obesity Treatment | 05/05/2026 | By News Bureau
UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment
The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.
Obesity Treatment | 15/04/2026 | By News Bureau | 130
Hoth Therapeutics Reports Positive HT-VA CRADA Data
Hoth Therapeutics reports positive HT-VA data showing GDNF improves liver fat metabolism, reduces fat production and may outperform semaglutide in MAFLD and obesity.
Obesity Treatment | 14/04/2026 | By News Bureau | 150
MetaVia Advances Obesity Drug Development with First Patient Dosed in DA-1726 Phase I Trial
MetaVia initiates Part 3 of its phase I trial for DA-1726, evaluating higher-dose strategies to enhance weight loss, metabolic outcomes and tolerability in obesity and cardiometabolic disease treatment.
Obesity Treatment | 13/04/2026 | By News Bureau
Emcure Slashes Price of Semaglutide-Based Weight Loss Drug Poviztra in India
Emcure reduces the price of its semaglutide-based drug Poviztra, aiming to make effective weight management treatment more accessible to patients across India.
Obesity Treatment | 04/04/2026 | By News Bureau | 131
UK MHRA Approves up to 7.2 mg Dose of Semaglutide for Obesity Treatment
The UK MHRA has approved a higher dose of semaglutide of up to 7.2 mg for weight management in adult patients with obesity. The regimen involves three 2.4 mg injections and is indicated for use alongside a reduced-calorie diet and increased physical activity in adults with a Body Mass Index (BMI) of 30 kg/m² or higher.
Obesity Treatment | 17/01/2026 | By News Bureau | 143
Novo Nordisk Introduces Wegovy Pill with knownwell as NovoCare Provider
Novo Nordisk has launched Wegovy in an oral pill form, marking the first FDA-approved oral GLP-1 therapy, with knownwell recognised as a NovoCare provider to support broader patient access to clinician-led metabolic care across the US.
Obesity Treatment | 06/01/2026 | By News Bureau | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy